End­points Man­u­fac­tur­ing: Charles Riv­er makes a splash for cell and gene ther­a­py spe­cial­ist; 5 ques­tions with Ho­mol­o­gy Med­i­cines

Af­ter a blis­ter­ing start to 2021, it seemed as though news in the biotech man­u­fac­tur­ing world had slowed to a more rea­son­able pace in the last few weeks.

Then the news came down Wednes­day of an ex­pen­sive merg­er in one of the fastest-grow­ing man­u­fac­tur­ing are­nas: cell and gene ther­a­peu­tics. And it comes with a $875 mil­lion cash price tag.

Charles Riv­er Lab­o­ra­to­ries, a play­er in the field for 75 years, bought out Cog­nate BioSer­vices, a cell and gene ther­a­py spe­cial­ist with op­er­a­tions in both North Amer­i­ca and Eu­rope. Pitched as an “ex­cep­tion­al strate­gic fit”, Cog­nate’s ser­vices will give Charles Riv­er a boost in so­lid­i­fy­ing its end-to-end man­u­fac­tur­ing ca­pac­i­ties for cell and gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER